Key result
The MMP3 6A allele was significantly more frequent in patients with cardiomyopathy compared to healthy controls (65.8% vs 59.3%, p=0.044).
Why the study?
The study was conducted to evaluate the relationship between the matrix metalloproteinase-3 (MMP3) genetic polymorphism and dilated ischemic cardiomyopathy as well as idiopathic cardiomyopathy of unknown etiology.
Is the MMP3 -11715A/6A polymorphism associated with dilated ischemic and idiopathic cardiomyopathy?
Case-Control (n=342)
Is the MMP3 -11715A/6A polymorphism associated with dilated ischemic and idiopathic cardiomyopathy?
Absolute Event Rate: 65.8% vs 59.3%
p-value: p=0.044
The MMP3 -11715A/6A polymorphism, specifically the 6A allele, is associated with an increased risk of dilated and idiopathic cardiomyopathy.
Aim. To study the relationship of matrix metalloproteinase-3 ( MMP3 ) genetic polymorphism and dilated ischemic cardiomyopathy (DCM), as well as idiopathic cardiomyopathy (ICM) of unknown etiology. Material and methods. A total of 221 patients with DCM and ICM were examined (mean age, 55,30±9,69 years). The group of ischemic DCM consisted of 111 people (99 men (89,2%) and 12 women (10,8%)). The mean age of DCM subjects was 51,73±9,74 years (male subgroup, 51,00±8,96 years; female subgroup, 57,75±3,71 years). The ICM group consisted of 110 people (100 men (91,5%) and 10 women (8.5%)). The mean age of ICM subjects was 58,68±8.38 years (male subgroup, 58,29±8.,6 years; female subgroup, 62,90±6,29 years). The control group of subjects (n=121) consisted of healthy people without cardiovascular diseases (mean age, 53,6±4,8 years). All patients of the experimental group underwent routine diagnostic tests, as well as coronary angiography. In case of suspected myocarditis, cardiac magnetic resonance imaging was performed. All patients underwent polymerase chain reaction to determine the MMP3 -11715A/6A polymorphism (rs35068180). Results. In patients with cardiomyopathy, regardless of the disease origin, significant differences were verified in comparison with the control group. Allele 6A (65,8% vs 59,3%, p=0,044) and genotype 6A/6A (42,1% vs 32,6%, p=0,099) were found significantly more frequently in patients with cardiomyopathy than in the control group. In addition, despite various etiological factors, the pathogenetic involvement of MMP3 is likely to have a general direction. Conclusion. In all patients with cardiomyopathy, the prevalence of MMP3 gene A allele was shown. Due to decrease in the transcription activity in homozygous 6A allele, the stromelysin level in arterial walls also decreases. This promotes the activation of procollagenase-1, the deposition of extracellular matrix and cardiac remodeling
No takes yet. Share an insight, caveat, or question.
Nikulinа et al. (2020) conducted a case-control in Dilated cardiomyopathy (n=342). MMP3 -11715A/6A polymorphism (rs35068180) vs. Healthy controls without cardiovascular diseases was evaluated on Frequency of Allele 6A (p=0.044). The MMP3 6A allele was significantly more frequent in patients with cardiomyopathy compared to healthy controls (65.8% vs 59.3%, p=0.044).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: